Arterin® – doplněk stravy v léčbě dyslipidemie: výsledky krátkodobého klinického sledování
Authors:
Miroslav Souček
Authors‘ workplace:
II. interní klinika LF MU a FN U sv. Anny v Brně
Published in:
AtheroRev 2016; 1(3): 160-163
Category:
Reviews
Overview
Elevated LDL-cholesterol levels are among the main risk factors for ischemic heart disease. It can be influenced by pharmacotherapy, but also by changes in eating and life habits. The most recent recommendations on the treatment of dyslipidemia devote special attention to nutritional supplements and functional foods.
Key words:
arterin (monacolin K) – dyslipidemia – cardiovascular complications – lipid spectrum
Sources
1. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: (25 Suppl. 2): S1-S45. Dostupné z DOI: <http://doi: 10.1161/01.cir.0000437738.63853.7a>.
2. Soška V, Vaverková H, Vráblík M et al. Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. Vnitř Lék 2013; 59(2): 120–126.
3. Catapano AL, Reiner Z, Backer CD et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3–46.
4. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9(7): 2304. Dostupné z DOI: <http://doi: 10.2903/j.efsa.2011.2304>.
5. Perin BS. Prospective Studie an 800 Patienten ARTERIN® 1× täglich (Monacolin K). (Archiv společnosti Omega Pharma).
6. Lu Z, Kou W, Du B et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101(12): 1689–1693. Dostupné z DOI: <http://doi: 10.1016/j.amjcard.2008.02.056>.
7. Venero CV, Venero JV, Wortham DC et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010; 105(5): 664–666. Dostupné z DOI: <http://doi: 10.1016/j.amjcard.2009.10.045>.
8. Becker DJ, Gordon RY, Halbert SC et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009; 150(12): 830–839. W147-A149.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2016 Issue 3
Most read in this issue
- Arterin® – doplněk stravy v léčbě dyslipidemie: výsledky krátkodobého klinického sledování
- Atherogenic dyslipidemia – a new target in cardiovascular prevention
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
- Peripheral arterial disease (PAD) of lower extremity and dyslipidemia